- Home
- DOLE vs CDTX Comparison
DOLE vs CDTX Comparison
Compare DOLE & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOLE
- CDTX
- Stock Information
- Founded
- DOLE 1851
- CDTX 2012
- Country
- DOLE Ireland
- CDTX United States
- Employees
- DOLE N/A
- CDTX N/A
- Industry
- DOLE Farming/Seeds/Milling
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DOLE Consumer Staples
- CDTX Health Care
- Exchange
- DOLE Nasdaq
- CDTX Nasdaq
- Market Cap
- DOLE 1.3B
- CDTX 1.4B
- IPO Year
- DOLE 2021
- CDTX 2015
- Fundamental
- Price
- DOLE $14.02
- CDTX $65.22
- Analyst Decision
- DOLE
- CDTX Strong Buy
- Analyst Count
- DOLE 0
- CDTX 11
- Target Price
- DOLE N/A
- CDTX $57.00
- AVG Volume (30 Days)
- DOLE 723.6K
- CDTX 479.3K
- Earning Date
- DOLE 08-11-2025
- CDTX 08-07-2025
- Dividend Yield
- DOLE 2.43%
- CDTX N/A
- EPS Growth
- DOLE N/A
- CDTX N/A
- EPS
- DOLE 0.25
- CDTX N/A
- Revenue
- DOLE $8,757,709,000.00
- CDTX N/A
- Revenue This Year
- DOLE $3.87
- CDTX N/A
- Revenue Next Year
- DOLE $1.93
- CDTX N/A
- P/E Ratio
- DOLE $11.76
- CDTX N/A
- Revenue Growth
- DOLE 4.75
- CDTX N/A
- 52 Week Low
- DOLE $12.20
- CDTX $10.14
- 52 Week High
- DOLE $17.12
- CDTX $66.95
- Technical
- Relative Strength Index (RSI)
- DOLE 48.03
- CDTX 72.50
- Support Level
- DOLE $13.30
- CDTX $60.30
- Resistance Level
- DOLE $14.55
- CDTX $64.26
- Average True Range (ATR)
- DOLE 0.36
- CDTX 3.19
- MACD
- DOLE -0.03
- CDTX -0.72
- Stochastic Oscillator
- DOLE 44.75
- CDTX 89.81
About DOLE Dole plc
Dole PLC operates in the North American and European markets for fresh fruits and vegetables. The company's segment includes Fresh Fruit; Diversified Fresh Produce - EMEA; Diversified Fresh Produce - Americas and ROW. It generates maximum revenue from the Diversified Fresh Produce - EMEA segment. Diversified Fresh Produce - EMEA segment includes Dole's Irish, Dutch, Spanish, Portuguese, French, Italian, U.K., Swedish, Danish, South African, Eastern European, and Brazilian businesses, the majority of which sell a variety of imported and local fresh fruits and vegetables through retail, wholesale and, in some instances, food service channels across the European marketplace.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.